NCT06079294 Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
| NCT ID | NCT06079294 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Autoimmune Encephalitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2024-05-31 |
| Primary Completion | 2026-04-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute phase, before immunomodulating treatment, or within 10 days of treatment initiation.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * Newly diagnosed autoimmune encephalitis based on at least 1 of the 3 following criteria : 1. " Definite limbic autoimmune encephalitis " according to 2016 Graus et al. criteria 2. " Possible autoimmune encephalitis " according to 2016 Graus et al. criteria AND typical autoantibody detected in serum or CSF 3. " Probable or certain paraneoplastic neurological syndrome " according to Graus et al. 2021 criteria (excluding peripheral neurological syndromes) * Less than 6 months since first neurological symptoms imputable to autoimmune encephalitis * Affiliated or entitled to a social security system (except AME) * Obtaining free, written and informed consent (patient or legal representative or the close relative) Exclusion criteria * History of brain tumor, head trauma, infarction or cerebral hematoma likely to result in altered cerebral carbohydrate metabolism on PET * Patients who hae been on immunotherapy (corticosteroid bolus, IVIg, plasma exch